NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX molecular thyroid test will now be covered by Cigna.

The test uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, and is designed to assess fine needle aspiration samples from indeterminate thyroid nodules.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.